415 Capital

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovations. With over 30 years of experience, the firm focuses exclusively on large unmet patient needs in chronic diseases, particularly cardio and neurovascular disorders, which are leading causes of death and significant cost drivers in global healthcare systems. Their mission is to improve patient outcomes and quality of life while reducing long-term healthcare costs.

The firm's investment strategy centers on clinical-stage innovations in medical technologies, emphasizing sectors such as structural heart disease, heart failure, aortic and peripheral vascular disease, neurovascular disease, hypertension, electrophysiology, neuromodulation for chronic diseases, medical imaging, medical robotics, and patient monitoring. They do not invest in biotech/pharma, healthcare services, or wellness products. 415 Capital typically invests between €5 million and €15 million per company, targeting clinical through commercial stages in Europe, Israel, and North America.

Over the years, 415 Capital has funded over 50 medical technology companies, achieving more than 25 realized exits through trade sales and IPOs. Their portfolio includes companies like Supira Medical, R3 Vascular, CorFlow Therapeutics, Distalmotion, and TRiCares. The firm leverages close collaborations with leading physicians and healthcare providers to support entrepreneurs from R&D through clinical trials and commercialization, providing access to a €2 billion commercial channel in Europe through partnerships with Uniphar PLC and CoRRect Medical GmbH. In October 2024, 415 Capital announced the launch of its second fund, 415 Capital Fund II, with a target of €150 million, focusing on advancing breakthrough medical technologies addressing cardiovascular and neurovascular diseases.